Skip to content

Basant Pradhan

3 papers in the library · 91 citations · publishing 2015-2022

Papers

Sort Most recent Most cited

Possible Role of Parvalbumin Interneurons in Meditation and Psychiatric Illness.

The Journal of Neuropsychiatry and Clinical Neurosciences 2022 Srinagesh Mannekote Thippaiah, Basant Pradhan, Emanuel Voyiaziakis et al.

Parvalbumin (PV) interneurons are present in multiple brain regions and produce complex influences on brain functioning. An increasing number of research findings indicate that the function of these interneurons is more complex than solely to inhibit pyramidal neurons in the cortex. They generate feedback and feedforward inhibition of cortical neurons, and they are critically involved in the...

DOI: 10.1176/appi.neuropsych.21050136 (opens in new tab) Full text (opens in new tab) Meditation Gamma oscillations Neuropsychiatric disorders neurophysiology Parvalbimun inhibitory interneurons

d-Serine is a potential biomarker for clinical response in treatment of post-traumatic stress disorder using (R,S)-ketamine infusion and TIMBER psychotherapy: A pilot study.

Biochimica et Biophysica Acta. Proteins and Proteomics March 18, 2018 Basant Pradhan, Ludmil Mitrev, Ruin Moaddell et al. 67 citations

Post-traumatic stress disorder (PTSD) is a chronic and debilitating condition that is often refractory to standard frontline antidepressant therapy. A promising new approach to PTSD therapy is administration of a single sub-anesthetic dose of (R,S)-ketamine (Ket). The treatment produces rapid and significant therapeutic response, which lasts for only 4-7 days. In one of our studies, the mean...

Ketamine, Transcranial Magnetic Stimulation, and Depression Specific Yoga and Mindfulness Based Cognitive Therapy in Management of Treatment Resistant Depression: Review and Some Data on Efficacy

Depression Research and Treatment 2015 Basant Pradhan, Tapan Parikh, Ramkrishna Makani et al. 24 citations

Depression affects about 121 million people worldwide and prevalence of major depressive disorder (MDD) in US adults is 6.4%. Treatment resistant depression (TRD) accounts for approximately 12–20% of all depression patients and costs $29–$48 billion annually. Ketamine and repetitive transcranial magnetic stimulation (rTMS) have useful roles in TRD, but their utility in long term is unknown. As...